RXC010 – Pan-KRAS Inhibitor Programme
Currently in IND-enabling
Pan-KRAS Inhibitor Programme
The KRAS inhibitor programme is targeting KRAS to inhibit oncogenic signaling and suppress KRAS mutant tumour growth. To date a number of inhibitors of the G12C variant of KRAS are in clinical development – Redx has targeted the next generation by focusing on a multi–KRAS profile which would inhibit other mutant forms of KRAS.
Currently launched KRAS inhibitors Lumakras (sotorasib) and Krazati (adagrasib) selectively target the KRAS G12C mutation, Redx is targeting next generation pan-KRAS profile that inhibits a broad range of KRAS mutants and also wild-type KRAS, which could help prevent the reported resistance observed with KRAS mutant selective agents.
Rat sarcoma virus (RAS) is the most frequently mutated oncogene across different cancer types, with KRAS mutations accounting for approximately 85% of these mutated oncogenes. Therefore, KRAS inhibitors targeting multiple commonly occurring mutations may offer a treatment option for large segments of colorectal, pancreatic and lung cancer patients who currently have limited treatment options. Developing orally-bioavailable agents with dosing that allows for long term target coverage, and thus reduced risk of resistance, is a key opportunity for the next wave of KRAS-targeting agents that act beyond the G12C mutation.
KRAS inhibitor programme sold to Jazz Pharmaceuticals (“Jazz”)
On 7 February 2024, Redx Pharma announced that it had signed a definitive agreement with Jazz under which Jazz acquired Redx’s KRAS inhibitor programme, which includes G12D selective and pan-KRAS molecules, for the treatment of KRAS mutant driven cancers.
Under the terms of the agreement, Jazz returned the rights to the KRAS programme to Redx in Q2 2026 following a decision by Jazz not to progress this programme into the clinic. Jazz retains certain royalties in the programme. Redx will pursue alternative partnering opportunities.
Pan-KRAS Inhibitor Programme
The KRAS inhibitor programme is targeting KRAS to inhibit oncogenic signaling and suppress KRAS mutant tumour growth. To date a number of inhibitors of the G12C variant of KRAS are in clinical development – Redx has targeted the next generation by focusing on a multi–KRAS profile which would inhibit other mutant forms of KRAS.
Currently launched KRAS inhibitors Lumakras (sotorasib) and Krazati (adagrasib) selectively target the KRAS G12C mutation, Redx is targeting next generation pan-KRAS profile that inhibits a broad range of KRAS mutants and also wild-type KRAS, which could help prevent the reported resistance observed with KRAS mutant selective agents.
Rat sarcoma virus (RAS) is the most frequently mutated oncogene across different cancer types, with KRAS mutations accounting for approximately 85% of these mutated oncogenes. Therefore, KRAS inhibitors targeting multiple commonly occurring mutations may offer a treatment option for large segments of colorectal, pancreatic and lung cancer patients who currently have limited treatment options. Developing orally-bioavailable agents with dosing that allows for long term target coverage, and thus reduced risk of resistance, is a key opportunity for the next wave of KRAS-targeting agents that act beyond the G12C mutation.
KRAS inhibitor programme sold to Jazz Pharmaceuticals (“Jazz”)
On 7 February 2024, Redx Pharma announced that it had signed a definitive agreement with Jazz under which Jazz acquired Redx’s KRAS inhibitor programme, which includes G12D selective and pan-KRAS molecules, for the treatment of KRAS mutant driven cancers.
Under the terms of the agreement, Jazz returned the rights to the KRAS programme to Redx in Q2 2026 following a decision by Jazz not to progress this programme into the clinic. Jazz retains certain royalties in the programme. Redx will pursue alternative partnering opportunities.